Single-dose intraincisional levobupivacaine infiltration in caesarean postoperative analgesia: a placebo-controlled double-blind randomized trial

• Published in: Annales françaises d'anesthésie et de réanimation 2013-01, Vol.32 (1), p.25-30
• Main Authors: Corsini, T, Cuvillon, P, Forgeot, A, Chapelle, C, Seffert, P, Chauleur, C
• Format: Article
• Language: fre
• Subjects: Adult; Analgesics, Opioid - administration & dosage; Analgesics, Opioid - therapeutic use; Anesthetics, Local - administration & dosage; Anesthetics, Local - therapeutic use; Bupivacaine - administration & dosage; Bupivacaine - analogs & derivatives; Bupivacaine - therapeutic use; Cesarean Section; Double-Blind Method; Endpoint Determination; Female; Humans; Infant, Newborn; Morphine - administration & dosage; Morphine - therapeutic use; Pain Measurement; Pain, Postoperative - drug therapy; Parity; Postoperative Nausea and Vomiting - epidemiology; Pregnancy
• ISSN: 1769-6623
• DOI: 10.1016/j.annfar.2012.10.035

The efficacy of single-dose intraincisional infiltration with levobupivacaine in postoperative analgesia and chronic pain after caesarean sections is unknown. A placebo-controlled double-blind randomized trial. After ethical approval, and written inform consent, 140 women scheduled for a caesarean section were randomly assigned and received 30mL of levobupivacaine 0.5% (L group) or saline (placebo-P group) into their wound. The primary endpoint was morphine consumption (using intravenous morphine patient-controlled analgesia) for the first 24h after surgery. At 1h to 48h, side effects, pain at rest and pain 2months later were recorded. All included patients had similar demographic and surgical characteristics. The morphine consumption was significantly lower in the L group at h6, h8 and h12 (considering both total intake and each request). At h4, the mean total morphine consumption was 25 (12) mg in the L group versus 31 (14) mg in the P group (P=0.05). Time until discharge and side effects including nausea-vomiting (14 vs 20%), wound scar complications (6 vs 8%) and chronic pain after 2months (25% in both groups complained of small pain, and 75% no pain) were similar between the two groups (P>0.05). Single-dose local infiltration of levobupivacaine 0.5% reduced opioid requirement at 12h, with no difference after 24h. www.clinicaltrials.com, number: NCT00621907.